US Physical Therapy (USPH) FY Conference June 11, 2025 10:45 AM ET Speaker0 Okay. We're gonna go ahead and get started with the next presentation. off, thank you everyone for being here today. My name is Joe Noyans. I'm with Three Part Advisors. Up next, we have one of our investor relations clients, US Physical Therapy. US Physical Therapy is traded on the New York Stock Exchange under the symbol USPH. They're operating in 44 states across The US with nearly 800 locations. Also, they're a leader in in PT, ...

Core Viewpoint - The earnings season for casino stocks has been generally positive, with companies like MGM Resorts and Las Vegas Sands performing well, while Bally's Corp has struggled, missing revenue targets for the sixth consecutive quarter but surprising with a profit [1][3]. Company Performance - Bally's reported revenue of $580.4 million, down 5.1% year-over-year, with 78% of this revenue coming from its casino business, which also saw a decline of 4.2% year-over-year [5]. - Despite missing revenue targets, Bally's achieved a profit of 58 cents per share, contrasting with analysts' expectations of a loss of 76 cents per share [3]. - The stock price of Bally's has only decreased by 2% following the earnings report, indicating some resilience in the face of volatility [4]. Market Context - The consumer discretionary sector is under scrutiny as investors assess the state of consumer spending, particularly in entertainment and gambling for 2024 and beyond [2]. - Bally's is expanding its omnichannel business, holding online sports betting licenses in 13 jurisdictions and growing its international presence through its Interactive International division [6]. Growth Strategy - Bally's is optimistic about its growth through acquisition strategy, having completed transactions that could add nearly 50% to its topline in the current year [7]. - The company has not held an earnings call for the third consecutive quarter, which has left analysts to interpret results without additional commentary [13]. Analyst Sentiment - Analysts have maintained a cautious stance on Bally's, with Barclays lowering its price target from $14 to $13 while keeping an Equal Weight rating [14]. - Bally's is not currently favored among top-rated analysts, who suggest alternative stocks for investment [15].